Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Feb 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat multiple myeloma, a type of blood cancer that can come back after treatment. The focus is on a special type of medicine called bispecific antibodies, which help the immune system fight cancer cells. In this trial, patients will receive increasing doses of these antibodies through three injections over about 10 days, followed by weekly treatments. The goal is to see if this outpatient approach is safe and effective, allowing patients to receive treatment without needing to stay in the hospital.

To participate in this trial, patients must be at least 18 years old and have multiple myeloma that has returned or has not improved with previous therapies. They should be in good health overall and live close enough to the treatment center for follow-up care. Participants can expect to receive careful monitoring during the treatment process, and the study aims to ensure that their quality of life remains stable. This trial not only seeks to find effective treatment options but also looks at how this approach can be cost-effective, helping to ensure that high-quality healthcare remains accessible for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Relapsed and/or refractory multiple myeloma
• • Treated with teclistamab, elranatamab ou talquetamab
• • More than 18 years old
• • Having received the information from the study and not having objected to participate
• • Day hospital care in case of clinical feasibility (good general condition, no rapid progression or major tumor burden, no current infection) and logistics (accommodated less than 30 minutes from the IUCT Oncopole for 48 hours after each dose escalation) or in conventional hospitalization at the IUCT Oncopole
• Exclusion Criteria:
• • Illiterate subjects or those with a language barrier